Bernstein Liebhard LLP Announces That Less Than Four Weeks Remain for Chemed Investors to Make a Motion for Lead Plaintiff

NEW YORK, Feb. 13, 2012 /PRNewswire/ -- Bernstein Liebhard LLP today announced that less than four weeks remain for Chemed Corporation ("Chemed" or the "Company") investors to make a motion for lead plaintiff with the Court.

(Logo: http://photos.prnewswire.com/prnh/20120202/MM47134LOGO )

Several weeks ago, a securities class action was commenced in the United States District Court for the Southern District of Ohio on behalf of purchasers of Chemed (NYSE:CHE) common stock during the period between February 15, 2010 and November 16, 2011 (the "Class Period").

The complaint charges Chemed and certain of its officers and directors with violations of the Securities Exchange Act of 1934.  Chemed, through its subsidiaries, provides hospice care and repair and cleaning services in the United States. The Company operates in two segments: VITAS and Roto-Rooter.

The complaint alleges that during the Class Period, defendants issued materially false and misleading statements regarding the Company's business and prospects. Specifically, defendants misrepresented and/or failed to disclose the following adverse facts: (a) that the Company engaged in a scheme to fraudulently bill Medicare for hospice services for patients who did not qualify for hospice and fraudulently shifted the costs of those patients from health maintenance organizations that covered those patients prior to enrollment in hospice to the U.S. government; (b) that a significant portion of the Company's hospice enrollments, revenues and earnings were the direct result of defendants' scheme to enroll ineligible patients in hospice and fraudulently bill Medicare for hospice services; (c) that, in a complaint filed under seal, a former VITAS manager had accused the Company of engaging in a Company-wide scheme to enroll ineligible patients in hospice and fraudulently bill Medicare; (d) that the Company failed to maintain adequate internal controls and procedures with respect to hospice enrollments and Medicare billings; (e) that the Company's financial results were materially overstated as a result of defendants' fraudulent scheme to enroll ineligible patients in hospice; and (f) that, as a result of the foregoing, defendants lacked a reasonable basis for their positive statements about the Company and its prospects.

On November 16, 2011, a Bloomberg article entitled "Whistleblower Accuses Chemed Unit of Medicare HMO Conspiracy" disclosed that a former VITAS manager had accused Chemed of defrauding the federal government by conspiring with health insurers to enroll Medicare patients who were not dying into hospice. The article also discussed a U.S. Department of Justice investigation into fraudulent conduct by VITAS. In response to these announcements, shares of the Company's stock fell $6.87 per share, or 11%, to close at $50.65 per share on November 16, 2011.

Plaintiffs seek to recover damages on behalf of all Class members who purchased or otherwise acquired Chemed shares during the Class Period.  If you purchased or otherwise acquired Chemed shares during the Class Period, and either lost money on the transaction or still hold the shares, you may wish to join in this action to serve as lead plaintiff.  In order to do so, you must meet certain requirements set forth in the applicable law and file appropriate papers no later than March 12, 2012.

A "lead plaintiff" is a representative party that acts on behalf of other class members in directing the litigation.  In order to be appointed lead plaintiff, the court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class.  Under certain circumstances, one or more class members may together serve as lead plaintiff.  Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff.  You may retain Bernstein Liebhard LLP, or other counsel of your choice, to serve as your counsel in this action.

If you are interested in discussing your rights as a Chemed shareholder and/or have information relating to the matter, please contact Joseph R. Seidman, Jr. at (877) 779-1414 or [email protected].

Bernstein Liebhard has pursued hundreds of securities, consumer and shareholder rights cases and recovered over $3 billion for its clients.  It has been named to The National Law Journal's "Plaintiffs' Hot List" in each of the last nine years.

You can obtain a copy of the complaint from the clerk of the court for the United States District Court for the Southern District of Ohio.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
(877) 779-1414
www.bernlieb.com

ATTORNEY ADVERTISING. © 2012 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Mary U. Hoover.  Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information

Joseph R. Seidman, Jr.
Bernstein Liebhard LLP
http://www.bernlieb.com
(212) 779-1414
[email protected]

SOURCE Bernstein Liebhard LLP